
Minerva Neurosciences (NERV) Stock Forecast & Price Target
Minerva Neurosciences (NERV) Analyst Ratings
Bulls say
Minerva Neurosciences is a potential promising pharmaceutical company with its product candidate, Roluperidone, showing positive results for treating negative symptoms in schizophrenia patients. With anticipated results of the phase 3 trial in 2027, the drug could potentially be the first approved therapy to target negative symptoms and potentially launch in 2029. Additionally, the expertise of the company's Chief Operating Officer in the life sciences industry adds to the potential success of the drug.
Bears say
Minerva Neurosciences is facing several major challenges that could ultimately impact its financial performance and stock performance. Despite potential for its product candidate, Roluperidone, to become a blockbuster treatment for schizophrenia, there is a lack of treatment options for negative symptoms and potential for global expansion. However, the company faces regulatory and litigation risks, and a missed Phase 3 study, which could delay or prevent approval and commercialization of its lead candidate. Additionally, the company has incurred significant warrant issuance costs, raising concerns about its capital and financial stability.
This aggregate rating is based on analysts' research of Minerva Neurosciences and is not a guaranteed prediction by Public.com or investment advice.
Minerva Neurosciences (NERV) Analyst Forecast & Price Prediction
Start investing in Minerva Neurosciences (NERV)
Order type
Buy in
Order amount
Est. shares
0 shares